Jobs / United States / Astrazeneca Pharmaceuticals Lp
Director of Cyber Threat Intelligence (CTI)
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Gaithersburg - MD
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
About AstraZeneca AstraZeneca is a global, science-led, patient-focused biopharmaceutical company dedicated to discovering, developing, and commercialising prescription medicines for serious disease. We’re committed to being a Great Place to Work. About the Role The Director of Cyber Threat Intelligence will lead a highly technical CTI function within AstraZeneca’s Cybersecurity Operations division, managing a team of analysts to deliver strategic, operational, and tactical intelligence that measurably reduces risk across the enterprise, including manufacturing, clinical trial platforms, and R&D environments. This role anchors CTI to “intel-to-action” outcomes, partnering closely with Vulnerability Management, Detection Engineering, and Incident Response to harden controls, prioritize patching, improve detections, and accelerate response. Key Responsibilities • Program Leadership and Strategy: Define CTI vision, operating model, and roadmap aligned to AstraZeneca’s cyber risk reduction strategy, with special emphasis on manufacturing continuity, clinical data integrity, and R&D IP protection. • Adversary Prioritization Framework: Design and operate a scoring rubric that ranks actors based on intent/capability/relevance, TTP emergence and prevalence, organization-specific exposure to known vulnerabilities/CVEs, and global “viral” events, maintaining dynamic watchlists and escalation triggers. • MTTI Metric and Analytics: Implement analytic methods to estimate mean time-to-impact per adversary (from initial access to material business impact) using internal telemetry, historical incidents, industry reporting, and confidence levels, performing comparisons with IR’s MTTC to drive control improvements. • Attack Path Modeling: Build and maintain end-to-end attack path models from initial access to material impact across IT-to-OT pivots, clinical platforms, and R&D environments, mapping steps to MITRE ATT&CK (Enterprise/ICS), identify control gaps and choke points, derive detections-as-code and hunt hypotheses, and support validation efforts including purple-team exercises and adversary emulation to ensure enterprise hardening and measurable risk reduction. • Dark Web and Closed-Source Monitoring: Establish collection and monitoring across dark web forums, marketplaces, breach dumps, and closed channels to identify emerging TTPs, credential leaks, data exposure, access-broker listings, and targeting of manufacturing, clinical, or R&D assets, integrating validated findings into TIP/SIEM pipelines, trigger takedown requests where feasible, and deliver rapid advisories with confidence ratings and specific actions for Vulnerability Management, Detection Engineering, and IR. • Third-Party and Ecosystem Intelligence: Deliver risk insights for CROs/CMOs/logistics/technology vendors, monitor credential leakage and domain spoofing, and support/coordinate takedown operations when needed. • Structured Threat Actor Attribution (Diamond Model): Lead disciplined attribution using the Diamond Model (adversary, capability, infrastructure, victim) and complementary frameworks, correlating TTPs, tooling lineage, code-reuse, infrastructure overlaps, and victimology with confidence levels and analytic caveats, documenting hypotheses, alternative explanations, and disconfirming evidence, and producing reusable actor profiles and pivot paths that inform prioritization, detections, hunts, and incident response playbooks. • Support Vulnerability Management: Partner with Vulnerability Management to contextualize CVEs (exploitability, weaponization, external scanning telemetry, compensating controls) and deliver risk-based patching prioritization across AstraZeneca’s estate including IT/OT, clinical platforms, and lab environments. • Su